scispace - formally typeset
Open AccessJournal ArticleDOI

Pattern of distant recurrence according to the molecular subtypes in Korean women with breast cancer

Reads0
Chats0
TLDR
Tailored strategies against distant metastasis concerning the molecular subtypes in breast cancer may be considered, and organ-specific metastasis may depend on the Molecular subtype of breast cancer.
Abstract
Distant recurrence is one of the most important risk factors in overall survival, and distant recurrence is related to a complex biologic interaction of seed and soil factors. The aim of the study was to investigate the association between the molecular subtypes and patterns of distant recurrence in patients with breast cancer. In an investigation of 313 women with breast cancer who underwent surgery from 1994 and 2000, the expressions of estrogen and progestrone receptor (ER/PR), and human epithelial receptor-2 (HER2) were evaluated. The subtypes were defined as luminal-A, luminal-HER2, HER2-enriched, and triple negative breast cancer (TNBC) according to ER, PR, and HER2 status. Bone was the most common site of distant recurrence. The incidence of first distant recurrence site was significantly different among the subtypes. Brain metastasis was more frequent in the luminal-HER2 and TNBC subtypes. In subgroup analysis, overall survival in patients with distant recurrence after 24 months after surgery was significantly different among the subtypes. Organ-specific metastasis may depend on the molecular subtype of breast cancer. Tailored strategies against distant metastasis concerning the molecular subtypes in breast cancer may be considered.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study

TL;DR: The pathological subtypes of breast cancer are clearly different in metastatic behavior with regard to the sites of distant metastasis, emphasizing that this knowledge may help to determine the appropriate strategy for follow-up and guide personalized medicine.
Journal ArticleDOI

The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer

TL;DR: Stage IV breast cancer patients have different clinicopathological characteristics and survival outcomes according to different metastatic sites, and patients with bone metastasis have the best prognosis, and brain metastasis is the most aggressive subgroup.
Journal ArticleDOI

The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based study.

TL;DR: It was proven that only bone metastasis was not a prognostic factor in the HR+/HER2-, HR+ /HER2+ and HR-/her2+ subgroup, and patients with brain metastasis had the worst cancer specific survival (CSS) in all the subgroups of BCS.
Journal ArticleDOI

Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype

TL;DR: Of the four subtypes, the LA subtype tends to have the best prognosis, fairly high survival, and low recurrent or metastases rates, and a statistically significant association between survival and molecular subtypes in an univariate analysis is demonstrated.
References
More filters
Journal ArticleDOI

Breast Cancer Subtypes and the Risk of Local and Regional Relapse

TL;DR: Molecular subtyping of breast tumors using a six-marker immunohistochemical panel can identify patients at increased risk of local and regional recurrence.
Journal ArticleDOI

Annual hazard rates of recurrence for breast cancer after primary therapy.

TL;DR: Patients 5 years postsurgery for breast cancer appear to have a very slowly decreasing hazard of recurrence, and this group of patients may be well suited for trials evaluating cytostatic drugs or differentiating agents.
Journal ArticleDOI

Subtypes of Breast Cancer Show Preferential Site of Relapse

TL;DR: The five major molecular subtypes in breast cancer are evidently different with regard to their ability to metastasize to distant organ(s), and share biological features and pathways with their preferred distant metastatic site.
Journal ArticleDOI

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

TL;DR: Women with HER‐2 overexpressing metastatic breast carcinoma benefit from trastuzumab‐based therapy, but trastzumab does not cross the blood‐brain barrier, and central nervous system (CNS) disease in these women is characterized.
Journal ArticleDOI

Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.

TL;DR: The purpose of the current study was to characterize the outcomes of patients with metastatic triple‐negative breast cancers, including the risk and clinical consequences of central nervous system (CNS) recurrence.
Related Papers (5)